Inhibitors of kinases involved in BCR signaling such as ibrutinib and idelalisib, along with BCL2 inhibitors such as venetoclax have underpinned the paradigm shift in CLL treatment. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.